A biweekly DPP ‐4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: A phase 2, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial

Ejemplares similares

• Efficacy and safety of bi‐weekly cofrogliptin treatment replacing daily dipeptidyl peptidase‐4 inhibitors in Chinese patients with type 2 diabetes mellitus: A multicenter, open‐label, randomized controlled phase 2 trial
  por: Congqing Pan, et al.
  Publicado: (2025)
• Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double‐blind, placebo‐controlled trial
  por: Yingying Xiang, et al.
  Publicado: (2024)
• Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial
  por: Leili Gao, et al.
  Publicado: (2024)
• A phase 2, randomized, multicenter, double‐blind, placebo‐controlled trial of S‐adenosyl methionine in participants with mild cognitive impairment or dementia due to Alzheimer's disease
  por: Sarah Holper, et al.
  Publicado: (2026)
• Influence of impaired glucose tolerance alone and combined with metabolic syndrome on long‐term risk of cardiovascular events and mortality
  por: Fei Chen, et al.
  Publicado: (2024)